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Abstract  
Raynaud’s phenomenon (RP) is a functional vascular disorder  involving extremities. In his 
practice, the dermatologist may frequently encounter RP which affects mainly women
A combination of conservative measures and medications can help in the management of 
RP. The importance of avoiding all potential physical, chemical and emotional triggers, as 
well as quitting smoking should be strongly suggested  to the patient. As first line 
treatment,  dihydropyridine Calcium Channel Blockers should be used. If this approach is 
not sufficient, prostacyclin derivatives, phosphodiesterases inhibitors and endothelin 
receptor antagonists can be considered as second line treatment. In cases of acute 
ischemia nifedipine and intravenous prostanoidsare helpful. In refractory cases, botulinum 
injections have shown a significant benefit. The approach to the RP patients requires 
therefore a coordinated care of  specialists together with the primary care physician. 
 and 
is categorized into a primary  benign form and a secondary form associated with  different 
diseases (infections, drugs, autoimmune and vascular conditions, hematologic, 
rheumatologic and endocrinologic disorders). Still today, the differential  diagnosis is a 
clinical challenge. Therefore, a careful history and a physical examination, together with 
laboratory tests and nailfold capillaroscopy are mandatory. RP is generally benign but a 
scheduled follow-up for primary RP patients should be established, due to risk of evolution 
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Introduction  
   Raynaud’s phenomenon (RP) is frequently encountered by the dermatologist in his 
practice and represents today a clinical challenge. It is defined as a bi- or tri-phasic color 
change of hands, feet, nose, earlobes and tongue, characterized by blanching (ischemia) 
followed by cyanosis (anoxia) and later by rubor (reperfusion) (Figure 1) . Pallor is the 
most specific sign and rubor is the least specific. RP can affect one or more digits; it is 
painful, intermittent, and lasts from few minutes to several hours. Currently RP is classified 
as a primary RP (pRP) that usually has a benign course, and secondary RP (sRP) that is 
associated with multiple etiologies.   
The aim of our work is to focus on the main problems that the dermatologist may have in 
managing RP in clinical practice. 
 
Frequency of Raynaud’s phenomenon  
The prevalence of RP is variable, ranging between 4%-15%. There are inconsistencies in 
the prevalence rate across geographical areas due to differences in the diagnostic 
methods, climate characteristics, and ethnicity within various populations (1). A higher 
prevalence of RP has been described in younger women. In a large USA study with a 16- 
years follow up, 9.6% of the women and 8.1% of men developed pRP (2). In another 
study, the population-based annual prevalence rates of RP was estimated as 3.6% for 
women and 1.4% for men, with women clearly having a higher risk for RP(3). The risk of 
RP was shown to increase consistently, yet modestly, with age (over 35 years), and 
decrease constantly with the decreased body mass index. (3) 
 
Triggers   
RP is usually triggered by an abrupt fall of temperature or by emotional stress. Moving 
from a warm environment to a colder one (outdoors in winter or air conditioned room in 
summer) can trigger RP attacks. There are many secondary triggers for RP – (i) cigarette 
smoking(4), (ii) medications (5), (iii) caffeine, (iv) occupations involving the constant use of 
vibrating tools or cold substances with an exponential increase in the risk after 12-years of 
work (3), (v) exposure to chlorinated and non-chlorinated solvents [acetone, toluene, 
xylene, etc.](6).  
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When a patient complains of blanching fingers followed by cyanosis and rubor, a 
methodological approach is required (Figure 2 ). The first step is to confirm the diagnosis 
of RP. This can be accomplished by a careful clinical history and physical examination. 
Most patients may not have active RP at the time of evaluation; thus it is helpful to verify 
RP by inspecting photographs taken by the patient at the time of an attack or  by the use  
of color charts that enable the patient to confirm the typical color changes (7). The next 
step is to determine if RP is pRP or sRP: a detailed history to identify possible etiologies, a 
careful physical examination, laboratory tests and nailfold capillaroscopy (NC) are  
essential at this stage. 
 
Primary RP is due to an exaggerated vasospastic response to cold or other stimuli and 
usually occurs in young women (8). It is characterized  by symmetrical attacks of  short 
duration (few minutes) in absence of any specific skin lesion (like digital ulcerations or 
scars), internal organ involvement or acral vascular complication. Apart from the history of 
RP upon exposure to any stimuli, the rest of the history and physical examination is 
usually unremarkable, including normal NC. (9) 
 
Secondary RP may involve both hands and may be, at the very onset, affecting only one 
finger. Usually, it is painful and lasts longer than pRP. It is suspected when the symptoms’ 
onset is over 30 years and/or complications occur [e.g. digital ulcers (DUs), pitting scars 
(8), secondary infection, tissue gangrene and auto or surgical amputation (10) (Figure 3 )]. 
(Table I  details the differences between pRP and sRP) 
Personal  history and clinical examination help in identifying potential causes of sRP (see 
Table II ) – occupational and environmental factors, smoking, medications (Table III ), 
symptoms and signs suggestive of a connective tissue disease (CTD), vascular disease, 
hematologic condition or infectious disease. 
A targeted laboratory work-up (autoantibodies and other serologies) may be helpful in 
identifying the cause. Further investigations, when needed, are guided by clinical 
evaluation. (The differential diagnosis are summarized in Table IV) . 
 
Since approximately 10 to 30% of RP patients can develop a CTD (11-13),  it is important 
to establish a scheduled follow-up with laboratory tests (e.g. complete blood count, 
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NC and/or abnormal serology (antinuclear, anticentromere or anti-Scl70 antibodies) are 
the best predictors for this progression.  
Among all CTDs, the most frequently developed disease is Systemic Sclerosis (SSc). (14) 
A study of 586 patients with RP without definite CTD reported that 12.6% developed SSc 
after a median duration of a 4-years follow-up. The presence of a scleroderma pattern at 
NC, and the presence of anti-nuclear (ANA), anti-centromere (ACA) and/ or anti 
topoisomerase-I antibodies (anti-Scl70) independently predicted the evolution to SSc(11). 
However, these signs  together with puffy fingers suggest a diagnosis of very early SSc, 
thus warranting further investigation of internal organs (15). Therefore, patients with RP 
and abnormal NC or positive serology should be labeled as “at risk for CTD” and followed 
periodically for detecting the potential transition to CTD.  
For what concerns other CTDs, a study of 3029 pRP patients reported that 37% of them 
developed CTD, the most frequent being an undifferentiated CTD (UCTD), followed by 
systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, overlap syndrome 
and systemic vasculitides. (14) 
 
Role of imaging  
Nailfold capillaroscopy  ( NC) is a very useful technique that can easily be performed with 
a stereomicroscope or an ophthalmoscope to identify microvascular changes suggestive of 
CTD. A scleroderma pattern (giant capillaries, micro-hemorrhages, architectural 
modifications and avascular areas) is typically found in SSc (Figure 4 )(16) and in a good 
proportion of patients with dermatomyositis (DM), with a high sensitivity and specificity 
(14,17,18). In contrast, in other CTDs (polymyositis (PM), systemic lupus erythematosus 
(SLE), Sjögren syndrome (SjS), rheumatoid arthritis (RA) and systemic vasculitides  
normal capillaries or non specific changes (such as elongated or enlarged capillaries or a 
slight capillary loss), are generally found, and cannot therefore be considered as predictive 
of the disease (14). Interestingly, a lack of association was found between the clinically 
involved digits and the degree of alterations seen at NC (19). 
When RP is asymmetric and tissue lesions are present in the digits, Doppler ultrasound  
may help to identify pathologic modifications of the arterial circulation, particularly in the 
ulnar arteries. However, the involvement of the digital arteries is difficult to demonstrate 
with Doppler, despite the fact that it is present in 63% of sRP and in 6% of pRP patients 
(20). In recurrent and complicated cases of sRP, conventional angiography or Magnetic 
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macrovasculature (21). These investigations are recommended to evaluate the potential of 
large to medium artery pathology, as seen in atherosclerosis, Takayasu vasculitis, and 
Buerger’s disease. These disorders are characterized by limb claudication on exercise, 
asymmetric abnormalities or an isolated and persistent digital ischemia, that can mimic 
RP. 
 
Role of outcome measures  
There has been a great deal of interest in developing disease activity and outcome 
measures in the clinical trial setting (22). In  RP clinical trials, patients are usually advised 
to maintain a diary to record the frequency and duration of RP attack, and at the end of 
each day they are advised to complete a Raynaud’s Condition Score (RCS). The RCS is a 
daily self-assessment of RP activity using a 0–10 ordinal scale. RCS incorporates the 
cumulative daily frequency, duration, severity, and impact of RP attacks on hand function. 
Other measures include patient and physician assessments of RP. However, the efficacy 
of these outcome measures has been fairly variable largely due to the subjective nature of 
the measures and also due to the placebo effect. A combination of items has been shown 
to be associated with lower placebo responses (23). 
 
Treatment of Raynaud’s phenomenon  
The initial management of RP aims to avoid RP triggers and to adapt lifestyle to patient’s 
need (24). Patients are advised to avoid or minimize cold exposure and thermal 
excursions, to dress warm and to have adequate insulation during cold weather and to 
keep their hands and feet warm with gloves and appropriate footwear. It is important to 
emphasize the value of quitting smoking. Patients should try to avoid emotional triggers, 
physical or chemical triggers and medications thought to cause RP. In most cases of pRP, 
pharmacotherapy is not required and lifestyle modifications are sufficient may control the 
symptoms (25). In contrast, pharmacological therapy, single or  combined, is often needed 
in sRP. 
 
Pharmacological therapy  
Recently, new recommendations have been issued focusing mainly on calcium channel 
blockers (CCBs), prostacyclin derivatives, Inhibitors of phosphodiesterases and endothelin 
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CCBs, especially dihydropyridine type CCBs, are the most commonly used group of 
medications as a first line treatment of RP. They relax vascular smooth muscle cells 
leading to vasodilation, and they also reduce platelet activation. They have been shown to 
reduce the number and severity of RP attacks and its complications. Nifedipine has been 
the most extensively studied (26) and recommended as the first line therapy to reduce the 
frequency and severity of RP in SSc patients (25). The newer second-generation CCBs 
(amlodipine, isradipine, nicardipine, felodipine) are also effective in reducing RP attacks. 
The treatment should start with a low dosage and titrated based on the tolerance and side 
effects in the individual patient. Common side effects of CCBs include headache, 
significant reduction of systemic blood pressure or peripheral edema. Based on the 
available evidence, oral CCBs like nifedipine or amlodipine should be used as initial choice 
of pharmacotherapy. 
If the therapy with CCBs is not effective in controlling the attacks, other therapies are 
recommended (Table V ) and an expert consultation should be obtained for further care. 
In patients who have to use a beta-blocker for cardiac indications, it is preferable to avoid 
the use of beta2-blockers (non-cardio selective) and use beta1-blockers (cardio selective) 
like carvedilol, labetalol and nebivolol although there are rare case reports of RP related  
to the use of beta1-blockers. (27,28). Gingko Biloba, herbal medications, acupuncture and 
other alternative therapies (laser and nutritional supplements) did not prove to impact the 
frequency, duration and severity of RP(29).  Moreover, temperature biofeedback is 
reported to be less efficacious than nifedipine in treating RP (30). Recently, a pilot single-
center, randomised controlled trial of acupressure versus targeted patient education in 
primary and secondary RP did not show any  efficacy for this technique (31). Recently, the 
use of ischemic preconditioning, which was thought to help potentially patients with RP, 
reducing the number of attacks, was found ineffective (32) 
. 
Emergencies in Raynaud’s phenomenon - the threatened digit  
Patients with chronic sRP, especially in the setting of CTD, can have episodes of acute 
digital or limb ischemia, which can rapidly progress to necrosis and gangrene. Early 
recognition and prompt vasodilating therapy is the key to avoid tissue loss. A detailed 
vascular examination is helpful; if peripheral pulses are feeble or absent, vascular imaging 
and vascular surgery consultation to assess the need for angioplasty/vascular intervention 
is needed to secure vessel potency and blood flow to the extremities. Nifedipine may be 
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limbs are at risk, an intravenous iloprost or epoprostenol infusion combined with 
anticoagulation (heparin, 5.000 UI twice daily) is preferable. A recent meta-analysis 
concluded that the use of iloprost in critical limb ischemia was efficacious in terms of pain 
relief, ulcer healing, and reduced need for amputations (33). These infusions are usually 
administered in a telemetry equipped wards under the care of cardiologists. Sympathetic 
block with anesthetics may also achieve a rapid vasodilatation. It is important to use 
effective analgesia, and local care of DUs with necrotic tissue debridement and infection 
control with appropriate antibiotics is crucial for full recovery. Therapeutic angiogenesis 
with autologous stem cells in patients lacking options for revascularization remains to be 
tested in future large-scale randomized trials (34). 
 
Conclusions  
The diagnosis of RP and categorization into pRP and sRP is very important and is  largely 
a clinical challenge for the dermatologist. Laboratory and imaging investigations are driven 
by clinical suspicion of secondary causes or due to concerns for peripheral vascular 
disease, respectively. Non-pharmacological management such as avoidance of RP 
triggers, peripheral and core re-warming and use of protective clothing are vital. If RP is 
severe or if ulcers occur, pharmacotherapy may be recommended to control the attacks. In 
sRP pharmacological therapy is usually needed, CCBs being the first line of treatment 
(nifedipine or amlodipine most frequently used). If the attacks persist despite maximal 
doses of CCBs, then other medical therapies are recommended, and referral to a 
specialist in RP should be considered.  
  In conclusion, the approach to RP is a coordinated care with various specialists involved 
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RP: raynaud’s phenomenon 
pRP: primary raynaud’s phenomenon 
sRP: secondary raynaud’s phenomenon 
NC: nailfold capillaroscopy 
DU: digital ulcer 
CTD: connective tissue disease 
SSc: systemic sclerosis  
ANA: anti-nuclear antibodies 
ACA: anti-centromere antibodies 
Anti-Scl70: anti topoisomerase-I antibodies  
UCTD: Undifferentiated CTD  
SLE: systemic lupus erythematosus 















Raynaud’s phenomenon  
 




SjS: Sjogren syndrome 
RCS: Raynaud’s Condition Score  
MRA: Magnetic Resonance Angiography 
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Table I: Classification of Raynaud’s phenomenon (RP)  
 
Primary RP  Secondary RP  
Young women [< 30 years] Patients aged >30 years 
Attacks are symmetric and are of short duration Attacks are asymmetric, extremely painful and 
prolonged 
No tissue lesions (digital pitting scars, 
telangiectasia) 
Tissue lesions seen 
No  complications (digital  ulcers, 
necrosis/gangrene) on the extremities 
Local complications common 
Normal nailfold capillaroscopy  Abnormal nailfold capillaroscopy in the setting 
of CTD 
Usually no suggestive features of CTD on 
clinical evaluation 
Association with CTD is common 
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Table II: Causes of secondary RP  
1. Autoimmune/Connective tissue diseases: Systemic Sclerosis, Systemic Lupus 
Erythematosus, dermatomyositis, polymyositis, Sjogren’s syndrome, primary biliary 
cirrhosis, Rheumatoid Arthritis  
2. Arterial diseases: thromboangiitis obliterans (Buerger’s disease), Takayasu 
vasculitis, giant cell arteritis, brachiocephalic atherosclerosis. 
3. Mechanical: vibration (white hand vibration syndrome), crutch pressure, thoracic 
outlet syndrome, scalenus anticus syndrome, cervical rib, carpal tunnel syndrome. 
4. Temperature: frostbite  
5. Endocrine disorders: carcinoid syndrome, pheochromocytoma, hypothyroidism 
6. Neoplasia:  ovarian carcinoma, angiocentric lymphoma. 
7. Rheological and coagulation disorders: cryoglobulins,  cryofibrinogenemia, cold 
agglutinins, paraproteinemia, plasmacytoma, polycythemia, 
microthromboembolism.   
8. Infections: parvovirus B19 , helicobacter pylori , hepatitis C and B, mycoplasma 
(cold agglutinins). 
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Drugs can induce RP mainly through 3 known mechanisms: enhanced vasoconstriction,  
endothelial damage or neurotoxicity and  increased blood viscosity 
 
Drug  Mechanism  
β-blockers Vasoconstriction via beta-adrenoreceptor blockade but still 
unclear. 
Clonidine α2 –adrenoreceptor agonist. In RP we already find a cold-
amplified α2-mediated vasoconstriction, augmented by 
clonidine action. (α2 receptor are located on smooth muscle 
cells) 
Ergot alkaloids Vasoconstriction via 5HT2 receptors on blood vessels + 
α1adr, α2adr, and dopamine receptor agonists. 
Dopamine agonists Such as bromocriptine, share the same mechanism as ergot 
alkaloids at high doses. 
Central stimulators of 
dopaminergic and 
noradrenergic system 
Peripheral release of catecholamines 
i.e. methylphenidate and dextroamphetamine, atomoxetine, 
reboxetine; amphetamine-like drugs like phentermine 
Cyclosporine Unclear, maybe vasospastic effect and alteration in blood 
viscosity 
Cocaine α2-adrenoreceptor mediated vasoconstriction 
Chemotherapies 3-6 months after starting. Drugs: bleomycin, vinca alkaloids, 
cisplatin mainly, less known for other therapies, 
Vinyl Chloride Occupational and/or environmental exposure 
Interferons (IFNs) IFNα>IFNβ>IFNγ, unclear, probably enhances 
vasoconstriction and increases blood viscosity. 
Tyrosine Kinase Inhibitors Unknown 
  
Potentially RP inducers  Few cases in literature  
Selective Serotonine 
Reuptake Inhibitors (SSRI) 
Contradictory data in the literature, apparently it depends on 
variability in serotonin patterns 
Sympathomimetics i.e. ephedrine. Only 1 patient reported in literature  
Sulfasalazine Unknown mechanism 
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Table IV: Physical characteristics of Raynaud’s phenomenon, Erythromelalgia, Acral 
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Erythromelalgia  Livedo Reticularis  







Primary / secondary 









netlike rings      





Mono/bilateral    Bilateral  Bilateral  
Pain  ++ Uncommon ++++ - 
Limb  Hands, feet, nose, ears, 
tongue 
Hands, feet Feet (may extend to 
hand,  ears and 
nose) 
Upper and lower 
limbs 
T° extremities   Cold  Cold       Hot  Cold  
Precipitated by   Cold Cold & 
lowering of the 
limb 
     Hot  Cold  
Phase/duration  Paroxistic/lasts from 





Intermittent/ may last 









position of the 
limb  
No change Normalizes 
when limb is 
elevated 
    No change    No change 
Complications  Digital Ulcers, 
gangrene, amputation 
None  None   None in primary,  
 in secondary  
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Table V: Therapies for Raynaud phenomenon  
 
Medication  Dose Side-effects  In practice  
Calcium channel blockers [CCB]  
Nifedipine 10 – 30 mg three 






First line medications  in RP. 
Also recommended when beta-




30 – 120 mg 
daily, oral 
Amlodipine 5 – 20 mg daily, 
oral 
Prostanoid derivatives  
Iloprost 0.5 – 2 ng/kg/min 





flush) or bowel activation 
(diarrhea, nausea) 
The use of iloprost in 
patients with myocardial 
ischemia and congestive 
heart failure  should be 
carefully monitored for a 
potential of a coronary 
steal syndrome or  
pulmonary edema  
Iloprost not available in USA, 
mainly used in Europe for the 
treatment of RP-SSc and 
critical limb ischemia 
Iloprost and alprostadil are 
both of benefit   RP- SSc-in 
practice; ease of handling and 
the lower price favor 
Alprostadil.  
No evidence of effect of 
Beraprost on the frequency, 
severity or duration of  RP 
attacks 
Repeated long-lasting 
epoprostenol infusion reduce 
RP but effect lost after 1 week. 
Alprostadil every 6–8 weeks, 
intravenous 
Beraprost  
Epoprostenol 2 ng/kg/min, with 
increase of 2 
ng/kg/min every 
30 minutes to the 
individually 
tolerated maximal 
dose of 8 
ng/kg/min, 
intravenous 
Phosphodiesterase -5 inhibitors (PDE5i)  
Sildenafil 
Total daily dose 
100 mg Headache, cutaneous 
flushing, dizziness, nasal 
congestion 
Reduces frequency, duration 
and severity of the attacks. 
Tadalafil 
20 mg at 
alternate days 
Improvement of RP symptoms 
and ulcer healing 
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attacks and improves 
Raynaud’s Condition Score 
Endothelin receptor antagonists (ERA)  
Bosentan   
Did not reduce frequency 
duration and pain of the 
attacks but prevented 
recurrence of DUs. 
    
Drugs interfering with  intracellular calcium activity  
Minoxidil topical minoxidil 
5% solution 
 Not effective in improving 
baseline digital blood flow or 
cold tolerance in RP 
Sympathetic blockade  
Prazosin 1 – 5 mg two 




Modest effect on RP. 










 Favorable results in many 
studies despite limitations. 
Improving of pain, severity, 
and reduction of DUs 
frequency 
Angiotensin – II receptor blocker  
Losartan 25 – 100 mg 
daily, oral 
Dizziness, hypotension One trial showed benefit in 
SSc patients with RP but 
seldom employed in  practice 
Serotonin re -uptake inhibitor  
Fluoxetine 20 – 40 mg daily, 
oral 
Apathy, lethargy and 
impaired concentration 
 
One trial showed benefit in 
SSc patients with RP but 
seldom employed in  practice 
Phosphodiesterase – 3 inhibitor  
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daily, oral nausea, diarrhea property 
Topical nitroglycerine  
Nitroglycerine 
patches 
0,2 mg/h (slow 
release) 
Headache 
Reduction of number and 





Improvement in frequency and 
duration of the attacks and of 
RPS  
Combination therapy: PDE5i + ERA  
Bosentan + sildenafil 
 
Reduction of late and active capillaroscopic 
















Figure 1 :  Asymmetric Raynaud’s phenomenon in a 28-year-old woman (blanching phase)    
 
Figure 2 :  a  stepwise approach to RP evaluation 
Abbreviations: NC= nail fold capillaroscopy, DU = digital ulcers, SSc= systemic sclerosis, 
SLE = systemic lupus erythematosus, EMG= electromyography, NCV = Nerve Conduction 
Velocity, TSH = thyroid stimulating hormone, TPO = thyroperoxidase, TG = thyroglobulin, 
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Figure 3:  Raynaud phenomenon in a 28-year-old woman with  antinuclear and anti-
centromere antibodies positivity,  active capillaroscopy pattern with one micro-hemorrhage 
(insert a). She was diagnosed with very early systemic sclerosis. The digital swelling 
worsened with the development of a digital ulcer in the third finger (insert b).  
 
 
Figure 4:  Raynaud phenomenon in a 57-year-old woman with puffy fingers. In the two 
inserts, capillaroscopy shows micro hemorrhages (a) and mega capillaries (b). The patient 
had antinuclear and anti-centromere antibodies without  any skin fibrosis. A diagnosis of 
very early systemic sclerosis was made.   
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